Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.

Kura will see more combo data, while a new contender from Sumitomo emerges.

Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.

Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.

Reports of Arc-10's failure are greatly exaggerated, the company argues.

The company abandons TNG908, but is still all in on the troubled target.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.